This site is intended for healthcare professionals
Venous Thromboembolism (VTE) Learning Zone
Declaration of sponsorship Pfizer and Bristol Myers Squibb


Declaration of sponsorship Pfizer and Bristol Myers Squibb
Read time: 350 mins
Last updated:27th Jul 2022
Published:25th Feb 2022

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and is associated with long-term complications, disability and significant mortality. Discover more about VTE, including:

  • Risk factors, prevalence and diagnosis of VTE
  • Key considerations for VTE management, including risk assessment, treatment options and treatment duration
  • Management of thrombosis in patients with cancer

In this learning zone, discover more about VTE including its prevalence and associated risk factors, how to assess a patient’s risk of bleeding and thrombosis, and why this is important for diagnosis and management. Explore recommendations on choice of anticoagulant based on the type of VTE and patient characteristics, as well as treatment duration and long-term follow-up.

Considering the higher risk of thrombosis in patients with cancer compared to the general population, explore the specific recommendations for risk assessment, thromboprophylaxis, and VTE treatment which may impact how you manage patients with cancer.

To learn more about how a patient’s risk of thrombosis and bleeding can inform decisions about VTE treatment, including the type, sequence and duration of anticoagulant treatment, view our infographic summary below.


Download infographic (PDF)

Meet the experts

About Professor Giancarlo Agnelli

Professor Giancarlo Agnelli is Professor of Internal Medicine at the University of Perugia, Italy, and Director of the Department of Internal and Cardiovascular Medicine and Stroke Unit at the University Hospital in Perugia, Italy. 


Professor Agnelli reports receiving lecture fees from Pfizer/BMS and serving as chair of a registry for Daiichi Sankyo.

Professor Stavros Konstantinides

Stavros Konstantinides is Professor for Clinical Trials and Medical Director of the Center for Thrombosis and Hemostasis at the University of Mainz, Germany. He is also Professor of Cardiology at the Democritus University of Thrace, Greece. For the past 30 years, his clinical and translational research has focused on the risk stratification and risk-adapted antithrombotic management of thrombosis and pulmonary embolism. He has designed and coordinated, and has been principal investigator of numerous high-impact national and international academically sponsored multicentre trials. He is leading member of national and European committees, task forces for clinical practice guidelines, and of networks on pulmonary circulation and right ventricular function.


Dr Konstantinides has received research grants from Bayer AG; consulting fees from Bayer AG, Daiichi-Sankyo and Boston Scientific and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer AG, Inari Medical, MSD, Boston Scientific, and Pfizer/BMS.